CN1124444A - 一水合葡萄糖或葡萄糖组合物 - Google Patents
一水合葡萄糖或葡萄糖组合物 Download PDFInfo
- Publication number
- CN1124444A CN1124444A CN94192255A CN94192255A CN1124444A CN 1124444 A CN1124444 A CN 1124444A CN 94192255 A CN94192255 A CN 94192255A CN 94192255 A CN94192255 A CN 94192255A CN 1124444 A CN1124444 A CN 1124444A
- Authority
- CN
- China
- Prior art keywords
- composition
- weight
- glucose
- vitamin
- intensity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 8
- 239000008103 glucose Substances 0.000 title claims description 7
- 239000008121 dextrose Substances 0.000 title 1
- 150000004682 monohydrates Chemical class 0.000 title 1
- 229960001031 glucose Drugs 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 13
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 159000000003 magnesium salts Chemical class 0.000 claims description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 8
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 238000004448 titration Methods 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 239000011787 zinc oxide Substances 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- 235000012245 magnesium oxide Nutrition 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 206010019133 Hangover Diseases 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000004087 circulation Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- -1 glucose group compound Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种组合物，其用以治疗“宿醉”——即人们过度消耗乙醇的延续效应。
Description
本发明背景
本发明涉及一种组合物，其用以治疗“宿醉”-即人们过度消耗乙醇的延续效应。
本发明摘要
本发明的目的是提供一种可单独(一种或多种剂量)使用以抵销宿醉的组合物。
本发明提供一种组合物，其含有大部分一水合葡萄糖或与下列化合物结合的葡萄糖：
(a)0.5-2％重量的抗坏血酸；
(b)顺势治疗滴定至6C强度或约0.4％重量的无毒钾盐；
(c)顺势治疗滴定至6C强度或约0.4％重量的无毒镁盐；
(d)0.001％-2.5％重量的维生素B6；
(e)顺势治疗滴定至6C强度或约0.07％重量的氧化锌；本发明详细描述
酒精在人体循环中一个已知的效果是降低血糖，由此而导致肝活性的增加，使得肝脏增加了其降解糖元为血糖的正常速率，从而恢复最适的血糖水平。肝脏活性的这种持续的或经常性的增加可导致肝硬化。
大脑消耗约25％的可利用血糖，因此血糖水平的降低会尤其迅速地影响大脑。因此，话语不清、记忆丧失、头痛、协调丧失、视力模糊、人格改变诸如此类的症候通常与酒精的消耗有关。
一水合葡萄糖在体内降解为葡萄糖，并且一水合葡萄糖和葡萄糖都迅速的吸收入血流以维持血糖水平，同时帮助预防肝损害以及抵销大脑功能失调。
循环中酒精的存在也被认为可增加排尿量和排尿频率，从而导致循环中维生素C(抗坏血酸)、镁和钾的丢失，同时必须补偿这些丢失以使系统正确恢复机能。适当的镁盐和钾盐的例子为硫酸镁、氧化镁和磷酸钾。
组合物中仅痕量镁盐和钾盐的存在被认为将足以刺激足够的该盐从机体自身的贮藏中释放出。本发明化合物效果的另一解释为，机体需要仅痕量的镁盐和钾盐来补偿由于酒精而引起的不足。但是，较高比例的镁盐和钾盐更有利。可使用一种或多种钾盐以及一种或多种镁盐。
另外认为，镁盐和钾盐以及维生素C更易于吸收入系统中，如果？一水合葡萄糖或葡萄糖有效地包被上述其它组分，从而防止其被胃酸破坏，同时加速其在系统中的循环。
氧化锌帮助胰腺产生胰岛素，从而有利于葡萄糖吸收入血。已知氧化锌在机体的解毒方面也是有效的，即抵抗酒精的延续效应。
组合物中维生素B6的存在被认为大大增加了组合物的活性，因此更迅速地缓解使用者。维生素B6和镁盐似乎是协同的，即其一的存在可增加另一个的效果，从而减少了组合物中每一个的用量而达到预期的效果。
因此，组合物中的组分用以提高使用者的血糖水平并且补充所丧失的维生素C、镁和钾，同时彼此相互作用而增加其的效果并加速其吸收入系统。
任意选择地，该组合物可含有一种或多种下列成分：
(a)0.5％-2％重量的粉末化柠檬酸，以改善组合物的可口性；
(b)0.5％-5％重量的粉末化磷酸钙，以补充钙的丢失。
本发明组合物一个优选的实例包括：
(a)2.4％抗坏血酸；
(b)1.1％柠檬酸；
(c)0.4％维生素B6；
(d)0.1％硫酸镁；
(e)0.1％磷酸钾；
(f)0.1％氧化镁；
(g)0.03％氧化锌；
(h)95.77％一水合葡萄糖；
(所有％重量)
该组合物为粉状，可溶于水中或片剂中。已发现，如果使用者在使用该组合物后右侧卧，则组合物更有效，因为这样可使组合物更快地通过十二指肠而进入小肠以吸收入系统。
可替换地，该组合物可制成液体形式，口服或注射给药。
Claims (6)
1.一种组合物包括：大部分一水合葡萄糖和或与下列化合物结合的葡萄糖：
(a)0.5-2％重量的抗坏血酸；
(b)顺势治疗滴定至6C强度或约0.4％重量的无毒钾盐；
(c)顺势治疗滴定至6C强度或约0.4％重量的无毒镁盐；
(d)0.001％-2.5％重量的维生素B6；
(e)顺势治疗滴定至6C强度或约0.07％重量的氧化锌。
2.权利要求1中所述的组合物，进一步包括0.5-2％重量的柠檬酸。
3.权利要求1或2所述的组合物，进一步包括0.5-2％重量的磷酸钙。
4.一种组合物含有
(a)2.4％抗坏血酸；
(b)1.1％柠檬酸；
(c)0.4％维生素B6；
(d)0.1％硫酸镁；
(e)0.1％磷酸钾；
(f)0.1％氧化镁；
(g)0.0 3％氧化锌；
(h)95.77％一水合葡萄糖；
(所有％重量)。
5.以上任一权利要求所述的组合物，其中所述组合物为粉状。
6.以上任一权利要求所述的组合物，其中所述组合物为液体形式。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ24770193 | 1993-05-26 | ||
| NZ247701 | 1993-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1124444A true CN1124444A (zh) | 1996-06-12 |
Family
ID=19924357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94192255A Pending CN1124444A (zh) | 1993-05-26 | 1994-05-10 | 一水合葡萄糖或葡萄糖组合物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0700255A4 (zh) |
| CN (1) | CN1124444A (zh) |
| AU (1) | AU676314B2 (zh) |
| CA (1) | CA2162877C (zh) |
| WO (1) | WO1994027449A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107217A (zh) * | 2013-04-18 | 2014-10-22 | Cj第一制糖株式会社 | 预防或治疗宿醉的组合物 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9601398D0 (en) * | 1996-01-24 | 1996-03-27 | Piper Edwina M | Composition |
| FR2748936A1 (fr) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Solution buvable favorisant la baisse du taux d'alcoolemie |
| FR2748904A1 (fr) * | 1996-05-27 | 1997-11-28 | Turpin Veronique | Complement nutritionnel personnalise a base de sels biochimiques de schuessler |
| WO1999026492A1 (fr) * | 1997-11-21 | 1999-06-03 | Turpin Veronique | Complement nutritionnel a base de sels biochimiques de schuessler |
| KR100309715B1 (ko) * | 1998-04-07 | 2001-12-28 | 이명희 | 구연산회로를활성화시켜알코홀독성과숙취를예방하는기능을가지는조성물 |
| KR100828708B1 (ko) * | 2007-06-19 | 2008-05-09 | 씨제이제일제당 (주) | 숙취의 예방 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH370631A (de) * | 1957-05-03 | 1963-07-15 | Heinrich Dr Vogler | Verfahren zur Herstellung eines als Zusatz zu Nahrungsmitteln und Getränken bestimmten Präparates |
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| NL8403433A (nl) * | 1984-11-09 | 1986-06-02 | Holland Melkunie | Voedingssuppletiepreparaat op basis van melkbestanddelen. |
| US5132113A (en) * | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
-
1994
- 1994-05-10 EP EP94913846A patent/EP0700255A4/en not_active Withdrawn
- 1994-05-10 CN CN94192255A patent/CN1124444A/zh active Pending
- 1994-05-10 CA CA002162877A patent/CA2162877C/en not_active Expired - Fee Related
- 1994-05-10 AU AU65844/94A patent/AU676314B2/en not_active Ceased
- 1994-05-10 WO PCT/NZ1994/000042 patent/WO1994027449A1/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107217A (zh) * | 2013-04-18 | 2014-10-22 | Cj第一制糖株式会社 | 预防或治疗宿醉的组合物 |
| CN104107217B (zh) * | 2013-04-18 | 2019-01-04 | Cj医药健康株式会社 | 预防或治疗宿醉的组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6584494A (en) | 1994-12-20 |
| WO1994027449A1 (en) | 1994-12-08 |
| EP0700255A1 (en) | 1996-03-13 |
| AU676314B2 (en) | 1997-03-06 |
| CA2162877C (en) | 2004-04-13 |
| CA2162877A1 (en) | 1994-12-08 |
| EP0700255A4 (en) | 1997-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1078057C (zh) | 运动饮料 | |
| US6136339A (en) | Food supplements and methods comprising lipoic acid and creatine | |
| US6632449B2 (en) | Compositions and kits comprising a defined boron compound and methods of their preparation | |
| DE60008238T2 (de) | Zusammensetzungen die kreatin in form einer suspension enthalten | |
| US4164568A (en) | Oral scour formulations with citrate | |
| DE60004797T2 (de) | Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure | |
| CN1124444A (zh) | 一水合葡萄糖或葡萄糖组合物 | |
| CH680569A5 (zh) | ||
| US5424074A (en) | Pharmaceutical composition for potassium supplementation | |
| LU87348A1 (de) | Magnesiumhaltiger mineralzusatz fuer naehrstoffe,nahrungsmittel und arzneimittel | |
| JPH02191223A (ja) | 鉄補給用発泡製剤 | |
| KR100613618B1 (ko) | 운동에 동반하여 일어나는 산화적 대사를 지속시키는 방법 및스포츠용 음식물 | |
| WO2006089317A1 (de) | Pharmazeutische mikrozirkulatorisch wirksame darreichungsform mindestens ein flavonoid enthaltend | |
| JP2003535120A (ja) | 低炭水化物組成物、そのキット、及びその使用方法 | |
| CA2408611A1 (en) | Kits and methods for optimizing the efficacy of chondroprotective compositions | |
| US20090062231A1 (en) | Appetite Suppressant Composition and Method of Appetite Suppression | |
| CA2246014C (en) | Food supplements and methods comprising lipoic acid and creatine | |
| CN1283083A (zh) | 复苏制剂 | |
| EP1093337B1 (en) | Food supplements comprising lipoic acid and creatine and methods for their use | |
| DE9412374U1 (de) | Nahrungsergänzungsmittel | |
| JP2617810B2 (ja) | カリウム補給発泡製剤 | |
| JP2002080376A (ja) | 生物活性剤および医薬 | |
| NZ265404A (en) | Composition for treatment of hangover | |
| JP3241173B2 (ja) | 入浴剤 | |
| WO2001093832A2 (en) | Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CI01 | Correction of invention patent gazette |
Correction item: International Day of publication Correct: 19941208 False: 19940812 Number: 24 Page: 124 Volume: 12 |
|
| ERR | Gazette correction |
Free format text: CORRECT: DATE OF THE INTERNATIONAL PROCLAMATION; FROM: 94.8.12 TO: 94.12.8 |
|
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |